Tourmaline Bio

Q3 2025 Q2 2025 +3.78%Q1 2025 +4.58%Q4 2024 -2.78%Q3 2024 +4.96%Q2 2024 +1.97%Q1 2024 -0.55%Q4 2023 +11.65%Q3 2023 -1.17%Q2 2023 +1.35%Q1 2023 -8.00%Q4 2022 +2.79%Q3 2022 +6.99%Q2 2022 -9.69%Q1 2022 +3.14%Q4 2021 +4.62%Q3 2021 -7.01%Q2 2021 -5.52%

Nov 12, 2021

•

Sep 30, 2021

Tourmaline Bio Q3 2021 Earnings Report

Reported financial results and provided a business update, highlighting progress in clinical trials and pipeline advancement.

Key Takeaways

Talaris Therapeutics announced its Q3 2021 financial results, reporting a net loss of $12.9 million, or $0.32 per share. The company highlighted the initial clinical update from its Phase 3 FREEDOM-1 trial and the initiation of the Phase 2 FREEDOM-2 clinical trial.

Provided initial clinical update from Phase 3 FREEDOM-1 trial evaluating FCR001 in living donor kidney transplant patients.

Initiated Phase 2 FREEDOM-2 clinical trial for FCR001 in delayed tolerance induction patients.

Presented updated long-term follow-up data from its Phase 2 LKDT study at the 2021 American Society of Nephrology meeting (ASN).

Finished the third quarter of 2021 with $254.7 million in cash, cash equivalents and marketable securities.